Treats major depressive disorder (MDD). ANDA 75932, held by Epic Pharma LLC. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 75932 (Bupropion Hydrochloride), held by Epic Pharma LLC, was first approved by FDA on Nov 25, 2003, with 30 approved supplements and 0 published complete response letters.
Bupropion hydrochloride extended-release tablets (SR) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD. The efficacy of bupropion hydrochloride extended-release tablets (SR) in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 25, 2003 | Original application | Approved |
| Bupropion Hydrochloride100MG · tablet, extended release;oral | Bupropion Hydrochloride | Rx |
| Bupropion Hydrochloride150MG · tablet, extended release;oral | Bupropion Hydrochloride | Rx |
| Bupropion Hydrochloride200MG · tablet, extended release;oral | Bupropion Hydrochloride | Rx |
| Mar 18, 2025 | Supplement 51Labeling · Standard review | Approved | None posted |
| Sep 2, 2022 | Supplement 49Labeling · Standard review | Approved | None posted |
| Jan 11, 2021 | Supplement 47Labeling · Standard review | Approved | None posted |
| Jan 11, 2021 | Supplement 46Labeling · Standard review | Approved | None posted |
| Jan 11, 2021 | Supplement 43Labeling · Standard review | Approved | None posted |
| Jul 15, 2016 | Supplement 40Labeling · Standard review | Approved | None posted |
| Jul 15, 2016 | Supplement 38Labeling · Standard review | Approved | None posted |
| Jul 15, 2016 | Supplement 35Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 34Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 33Labeling · Standard review | Approved | None posted |
| Apr 18, 2012 | Supplement 31Labeling | Approved | None posted |
| Oct 25, 2010 | Supplement 30Labeling | Approved | None posted |
| Sep 8, 2010 | Supplement 29Labeling | Approved | None posted |
| Apr 5, 2010 | Supplement 27Labeling | Approved | None posted |
| Nov 5, 2009 | Supplement 26Labeling | Approved | None posted |
| Oct 31, 2008 | Supplement 24Labeling | Approved | None posted |
| Feb 5, 2008 | Supplement 21Labeling | Approved | None posted |
| Jun 4, 2007 | Supplement 20Labeling | Approved | None posted |
| Nov 6, 2006 | Supplement 18Labeling | Approved | None posted |
| Aug 1, 2005 | Supplement 15Labeling | Approved | None posted |
| Jun 22, 2005 | Supplement 13 | Approved | None posted |
| Jun 22, 2005 | Supplement 12 | Approved | None posted |
| Jun 22, 2005 | Supplement 5Labeling | Approved | None posted |
| Jun 22, 2005 | Supplement 4 | Approved | None posted |
| Nov 18, 2004 | Supplement 14Labeling | Approved | None posted |
| Nov 18, 2004 | Supplement 10Labeling | Approved | None posted |
| Nov 18, 2004 | Supplement 3Labeling | Approved | None posted |
| Apr 28, 2004 | Supplement 9Labeling | Approved | None posted |
| Mar 22, 2004 | Supplement 2Labeling | Approved | |
| Mar 22, 2004 | Supplement 1 | Approved | |
| Nov 25, 2003 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters